Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1
Public ClinicalTrials.gov record NCT04795713. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This will be a Phase 1 Open-label, dose escalation and expansion study of MT-6402 (an Engineered Toxin Body (ETB)) in subjects with advanced solid cancer that expresses PD-L1
Study identification
- NCT ID
- NCT04795713
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 64 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 27, 2021 (Actual)
- Primary completion
- Oct 31, 2024 (Actual)
- Completion
- Oct 31, 2024 (Actual)
- Last update posted
- Nov 4, 2024
2021 – 2024
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Medical Center | Duarte | California | 91010 | — |
| USC Medical Center | Los Angeles | California | 90033 | — |
| Cedars Sinai Medical Center | Los Angeles | California | 90048 | — |
| Comprehensive Care and Research Center - Atlanta | Newnan | Georgia | 30265 | — |
| Comprehensive Care and Research Center - Chicago | Chicago | Illinois | 60099 | — |
| University of Louisville Health - Brown Cancer Center | Louisville | Kentucky | 40202 | — |
| Washington University School of Medicine - St. Louis | St Louis | Missouri | 63110 | — |
| Dartmouth Hitchcock | Lebanon | New Hampshire | 03766 | — |
| Carolina BioOncology | Huntersville | North Carolina | 28078 | — |
| Pennsylvania Cancer Specialists and Research Institute | Gettysburg | Pennsylvania | 17325 | — |
| Prisma Health | Greenville | South Carolina | 29605 | — |
| Sanford Cancer Center | Sioux Falls | South Dakota | 57104 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
| Mary Crowley Cancer Research | Dallas | Texas | 75230 | — |
| Oncology Consultants | Houston | Texas | 77024 | — |
| South Texas Accelerated Research Therapeutics, LLC | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04795713, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 4, 2024 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04795713 live on ClinicalTrials.gov.